Related Experiment Video
Updated: May 23, 2025

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
Paliperidone-induced neuroleptic malignant syndrome: A case report
1Clinic of Psychiatry, Mersin Sehir Egitim ve Arastirma Hastanesi, Toroslar, Mersin, Turkey.
Rationale:
Neuroleptic malignant syndrome (NMS) is a rare, life-threatening complication of neuroleptic (antipsychotic) medications. Paliperidone is an atypical antipsychotic used in the treatment of schizophrenia. While current evidence suggests that atypical oral antipsychotics have a lower incidence of NMS compared to typical oral antipsychotics, there is limited information available on the incidence and management of NMS associated with long-acting injectable (LAI) antipsychotics. More case studies are needed to fully understand the true incidence of NMS associated with LAI atypical antipsychotics. This report aims to present our experience with a patient with schizophrenia who developed NMS as a result of taking LAI paliperidone, an atypical antipsychotic.
Patient Concerns:
A 63-year-old male diagnosed with schizophrenia was brought to the emergency room with complaints of high fever, muscle contraction, tremors, urinary and fecal incontinence, and a change of consciousness, which started 2 days after the first LAI paliperidone injection. During the psychiatric examination, the patient exhibited tremors, a high fever of 39.5°C, and muscle rigidity. He was confused and had impaired orientation. The patient's creatine kinase, white blood cell count, aspartate aminotransferase, and alanine aminotransferase levels were measured at 1895 U/L, 13750/mm3, 55 IU/L, and 45 IU/L, respectively. The electrocardiogram showed sinus tachycardia.
Diagnoses:
The patient's psychiatric examination, vital signs, and laboratory results were consistent with NMS.
Interventions:
The patient received treatment with bromocriptine and amisulpride for 13 days.
Outcomes:
With this treatment, the patient's delirium improved and the patient became stable. The levels of creatine kinase, white blood cell count, aspartate aminotransferase, and alanine aminotransferase decreased to normal values. The patient was discharged from the hospital after 14 days of treatment.
Lessons:
Although NMS is not very common in patients using antipsychotics, it is important because it is an emergency condition that can result in death if not treated appropriately. Clinicians should consider NMS in patients taking atypical antipsychotics such as paliperidone.
Insights
Neuroleptic malignant syndrome (NMS) is a rare but serious complication of antipsychotic medications. This case study highlights NMS in a patient treated with long-acting injectable paliperidone, emphasizing the need for clinical vigilance.
Area of Science:
- Neuroscience
- Pharmacology
- Psychiatry
Background:
- Neuroleptic malignant syndrome (NMS) is a critical, potentially fatal adverse reaction to neuroleptic medications.
- Paliperidone, an atypical antipsychotic, is used for schizophrenia treatment.
- Limited data exists on NMS incidence with long-acting injectable (LAI) antipsychotics, necessitating further case studies.
Purpose of the Study:
- To report a case of NMS in a patient receiving LAI paliperidone.
- To contribute to understanding NMS associated with LAI atypical antipsychotics.
Main Methods:
- A 63-year-old male with schizophrenia presented with fever, muscle rigidity, and altered consciousness 2 days post-LAI paliperidone initiation.
- Clinical examination revealed fever (39.5°C), tremors, rigidity, confusion, and elevated creatine kinase (1895 U/L).
- Diagnosis of NMS was confirmed through clinical presentation and laboratory findings.
Main Results:
- The patient received bromocriptine and amisulpride for 13 days.
- Significant improvement in delirium and stabilization of vital signs were observed.
- Laboratory markers normalized, and the patient was discharged after 14 days.
Conclusions:
- NMS is a rare but critical emergency associated with antipsychotic use, including atypical agents like paliperidone.
- Clinicians must maintain a high index of suspicion for NMS in patients on atypical antipsychotics, especially LAI formulations.
- Prompt recognition and treatment are crucial for managing NMS and preventing mortality.
More Related Videos
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Mania and Antimanic Drugs: Overview
Parkinson's Disease: Overview
Antipsychotic Drugs: Therapeutic Uses and Side Effects
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neural Regulation

